{"preliminary_commentary":{"by_channel":{"x_thread":29,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT00114101\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["lenalidomide"]],"indication":"multiple myeloma","name":"CALGB 100104","nct_id":"NCT00114101","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=calgb-100104-nct00114101. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Beginning between day 100-110, patients receive lenalidomide PO once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.","label":"Arm I (melphalan, autologous PBSCT, lenalidomide)","type":"EXPERIMENTAL"},{"description":"Beginning between day 100-110, patients receive placebo PO once daily. Treatment continues in the absence of disease progression or unacceptable toxicity.","label":"Arm II (melphalan, autologous PBSCT, placebo)","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-03-06","type":"ESTIMATED"},"conditions":["DS Stage I Multiple Myeloma","DS Stage II Multiple Myeloma","DS Stage III Multiple Myeloma","Refractory Multiple Myeloma","Smoldering Multiple Myeloma"],"enrollment":{"count":460,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Autologous Hematopoietic Stem Cell Transplantation","otherNames":["AHSCT","Autologous","Autologous Hematopoietic Cell Transplantation","Autologous Stem Cell Transplant","Autologous Stem Cell Transplantation","Stem Cell Transplantation, Autologous"],"type":"PROCEDURE"},{"name":"Laboratory Biomarker Analysis","otherNames":[],"type":"OTHER"},{"name":"Lenalidomide","otherNames":["CC 5013","CC-5013","CC5013","CDC 501","Revlimid"],"type":"DRUG"},{"name":"Melphalan","otherNames":["Alanine Nitrogen Mustard","CB-3025","L-PAM","L-Phenylalanine Mustard","L-Sarcolysin","L-Sarcolysin Phenylalanine mustard","L-Sarcolysine","Melphalan for Injection-Hepatic Delivery System","Melphalanum","Phenylalanine Mustard","Phenylalanine Nitrogen Mustard","Sarcoclorin","Sarkolysin","WR-19813"],"type":"DRUG"},{"name":"Peripheral Blood Stem Cell Transplantation","otherNames":["PBPC transplantation","PBSCT","Peripheral Blood","Peripheral Blood Progenitor Cell Transplantation","PERIPHERAL BLOOD STEM CELL TRANSPLANT","Peripheral Stem Cell Support","Peripheral Stem Cell Transplant","Peripheral Stem Cell Transplantation"],"type":"PROCEDURE"},{"name":"Placebo Administration","otherNames":[],"type":"OTHER"}],"last_update":"2026-11-13","lead_sponsor":"National Cancer Institute (NCI)","official_title":"A Phase III Randomized, Double-Blind Study of Maintenance Therapy With CC-5013 (NSC # 703813) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2012-12-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Time to Progression","timeFrame":"Duration of study (up to 10years)"}],"references":[{"citation":"Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017 Sep;4(9):e431-e442. doi: 10.1016/S2352-3026(17)30140-0. Epub 2017 Aug 17.","pmid":"28826616","type":"DERIVED"},{"citation":"McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10;366(19):1770-81. doi: 10.1056/NEJMoa1114083.","pmid":"22571201","type":"DERIVED"}],"start_date":{"date":"2004-12-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant","url":"https://clinicaltrials.gov/study/NCT00114101"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/calgb-100104-nct00114101"}